Promising prostate cancer trial for hispanic and black patients pulled before start

NCT ID NCT06392841

Terminated Disease control Sponsor: Qian Qin Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This was a phase 2 trial testing a combination of niraparib and abiraterone plus prednisone for metastatic hormone-sensitive prostate cancer in Hispanic/Latino and Black patients with specific gene mutations. The study aimed to enroll 64 people but was withdrawn before any participants were recruited. No results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Niraparib and abiraterone acetate plus prednisone
What this could lead to: If successful, this could point toward a more effective treatment option for metastatic prostate cancer in Hispanic/Latino and Black patients with specific genetic mutations.
What could go wrong: The trial was withdrawn before enrolling any participants, so no data is available. It is unclear if the combination therapy would be safe or effective in this population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRCA1 GENE MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRCA1 GENE MUTATION BRCA2 GENE MUTATION BRIP1 GENE MUTATION CHEK2 GENE MUTATION DELETERIOUS HRR GENE MUTATION FANCA GENE MUTATION METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) PALB2 GENE MUTATION RAD51B GENE MUTATION RAD54L GENE MUTATION

More trials for these conditions

Other studies related to the condition(s) this trial covers.